Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system

PLoS One. 2017 Dec 22;12(12):e0190179. doi: 10.1371/journal.pone.0190179. eCollection 2017.

Abstract

Type 1 iodothyronine deiodinase (DIO1) contributes to deiodination of 3,5,3',5'-tetraiodo-L-thyronine (thyroxine, T4) yielding of 3,5,3'-triiodothyronine (T3), a powerful regulator of cell differentiation, proliferation, and metabolism. Our previous work showed that loss of DIO1 enhances proliferation and migration of renal cancer cells. However, the global effects of DIO1 expression in various tissues affected by cancer remain unknown. Here, the effects of stable DIO1 re-expression were analyzed on the proteome of renal cancer cells, followed by quantitative real-time PCR validation in two renal cancer-derived cell lines. DIO1-induced changes in intracellular concentrations of thyroid hormones were quantified by L-MS/MS and correlations between expression of DIO1 and potential target genes were determined in tissue samples from renal cancer patients. Stable re-expression of DIO1, resulted in 26 downregulated proteins while 59 proteins were overexpressed in renal cancer cells. The 'downregulated' group consisted mainly of oncoproteins (e.g. STAT3, ANPEP, TGFBI, TGM2) that promote proliferation, migration and invasion. Furthermore, DIO1 re-expression enhanced concentrations of two subunits of thyroid hormone transporter (SLC7A5, SLC3A2), enzymes of key pathways of cellular energy metabolism (e.g. TKT, NAMPT, IDH2), sex steroid metabolism and anti-oxidative response (AKR1C2, AKR1B10). DIO1 expression resulted in elevated intracellular concentration of T4. Expression of DIO1-affected genes strongly correlated with DIO1 transcript levels in tissue samples from renal cancer patients as well as with their poor survival. This first study addressing effects of deiodinase re-expression on proteome of cancer cells demonstrates that induced DIO1 re-expression in renal cancer robustly downregulates oncoproteins, affects key metabolic pathways, and triggers proteins involved in anti-oxidative protection. This data supports the notion that suppressed DIO1 expression and changes in local availability of thyroid hormones might favor a shift from a differentiated to a more proliferation-prone state of cancer tissues and cell lines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Antioxidants / metabolism*
  • Cell Line, Tumor
  • Down-Regulation*
  • Humans
  • Iodide Peroxidase / metabolism*
  • Kidney Neoplasms / enzymology*
  • Kidney Neoplasms / metabolism
  • Kidney Neoplasms / pathology
  • Oncogene Proteins / metabolism*
  • Proteomics
  • Real-Time Polymerase Chain Reaction
  • Thyroxine / metabolism

Substances

  • Antioxidants
  • Oncogene Proteins
  • iodothyronine deiodinase type I
  • Iodide Peroxidase
  • Thyroxine

Grant support

The work was supported by National Science Centre, Poland (https://www.ncn.gov.pl), grant no: 2014/13/B/NZ5/00283 (to APW); The Priority Programme 1629 ThyroidTransAct of the Deutsche Forschungsgemeinschaft DFG (grant KO-922/17-2, to JK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.